Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
47
ESLOY Quote, Financials, Valuation and Earnings
Last price:
$177.23
Seasonality move
:
3.45%
Day range:
$178.49 - $180.52
52-week range:
$118.18 - $186.81
Dividend yield:
1.25%
P/E ratio:
64.33x
P/S ratio:
5.63x
P/B ratio:
52.43x
Volume:
23.7K
Avg. volume:
45.1K
1-year change:
50.6%
Market cap:
$166.4B
Revenue:
$28.7B
EPS (TTM):
$2.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ESLOY
EssilorLuxottica SA
|
-- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$9.6M | -$0.10 | -5.7% | -56.58% | $7.20 |
|
DBVT
DBV Technologies SA
|
$889.9K | -$0.34 | -- | -77.25% | $20.57 |
|
IPHA
Innate Pharma SA
|
$2.3M | -- | -- | -- | $5.15 |
|
IVA
Inventiva SA
|
$10.1M | -$0.29 | -- | -- | $15.33 |
|
NBTX
Nanobiotix SA
|
-- | -- | -- | -- | $14.74 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ESLOY
EssilorLuxottica SA
|
$180.39 | -- | $166.4B | 64.33x | $2.25 | 1.25% | 5.63x |
|
CLLS
Cellectis SA
|
$4.66 | $7.20 | $467.5M | -- | $0.00 | 0% | 5.80x |
|
DBVT
DBV Technologies SA
|
$12.99 | $20.57 | $355.4M | -- | $0.00 | 0% | -- |
|
IPHA
Innate Pharma SA
|
$1.90 | $5.15 | $175.1M | -- | $0.00 | 0% | 24.54x |
|
IVA
Inventiva SA
|
$4.14 | $15.33 | $603.9M | -- | $0.00 | 0% | 24.10x |
|
NBTX
Nanobiotix SA
|
$21.03 | $14.74 | $1B | -- | $0.00 | 0% | 29.34x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ESLOY
EssilorLuxottica SA
|
21.86% | 0.350 | -- | 0.63x |
|
CLLS
Cellectis SA
|
54.27% | 0.665 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -1.892 | 5.85% | 1.41x |
|
IPHA
Innate Pharma SA
|
55.22% | -1.046 | -- | 2.76x |
|
IVA
Inventiva SA
|
-145.15% | -0.179 | 32.05% | 0.43x |
|
NBTX
Nanobiotix SA
|
195.9% | 4.777 | 20.12% | 1.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ESLOY
EssilorLuxottica SA
|
-- | -- | 4.89% | 6.07% | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
IPHA
Innate Pharma SA
|
-- | -- | -39.78% | -72.79% | -- | -- |
|
IVA
Inventiva SA
|
-- | -- | -- | -- | -- | -- |
|
NBTX
Nanobiotix SA
|
-- | -- | -161.14% | -- | -- | -- |
EssilorLuxottica SA vs. Competitors
-
Which has Higher Returns ESLOY or CLLS?
Cellectis SA has a net margin of -- compared to EssilorLuxottica SA's net margin of 1.68%. EssilorLuxottica SA's return on equity of 6.07% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About ESLOY or CLLS?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 54.51%. Given that Cellectis SA has higher upside potential than EssilorLuxottica SA, analysts believe Cellectis SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 CLLSCellectis SA2 2 0 -
Is ESLOY or CLLS More Risky?
EssilorLuxottica SA has a beta of 1.035, which suggesting that the stock is 3.545% more volatile than S&P 500. In comparison Cellectis SA has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.784%.
-
Which is a Better Dividend Stock ESLOY or CLLS?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.25%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or CLLS?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $35M. EssilorLuxottica SA's net income of -- is lower than Cellectis SA's net income of $586.4K. Notably, EssilorLuxottica SA's price-to-earnings ratio is 64.33x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 5.63x versus 5.80x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA5.63x 64.33x -- -- CLLSCellectis SA5.80x -- $35M $586.4K
-
Which has Higher Returns ESLOY or DBVT?
DBV Technologies SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of 6.07% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About ESLOY or DBVT?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $20.57 which suggests that it could grow by 58.35%. Given that DBV Technologies SA has higher upside potential than EssilorLuxottica SA, analysts believe DBV Technologies SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 DBVTDBV Technologies SA3 0 1 -
Is ESLOY or DBVT More Risky?
EssilorLuxottica SA has a beta of 1.035, which suggesting that the stock is 3.545% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.
-
Which is a Better Dividend Stock ESLOY or DBVT?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.25%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or DBVT?
EssilorLuxottica SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, EssilorLuxottica SA's price-to-earnings ratio is 64.33x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 5.63x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA5.63x 64.33x -- -- DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns ESLOY or IPHA?
Innate Pharma SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of 6.07% beat Innate Pharma SA's return on equity of -72.79%.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B IPHAInnate Pharma SA-- -- $68.9M -
What do Analysts Say About ESLOY or IPHA?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 171.26%. Given that Innate Pharma SA has higher upside potential than EssilorLuxottica SA, analysts believe Innate Pharma SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 IPHAInnate Pharma SA3 2 0 -
Is ESLOY or IPHA More Risky?
EssilorLuxottica SA has a beta of 1.035, which suggesting that the stock is 3.545% more volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.148%.
-
Which is a Better Dividend Stock ESLOY or IPHA?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.25%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or IPHA?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, EssilorLuxottica SA's price-to-earnings ratio is 64.33x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 5.63x versus 24.54x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA5.63x 64.33x -- -- IPHAInnate Pharma SA24.54x -- -- --
-
Which has Higher Returns ESLOY or IVA?
Inventiva SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of 6.07% beat Inventiva SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B IVAInventiva SA-- -- -$34.6M -
What do Analysts Say About ESLOY or IVA?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 270.37%. Given that Inventiva SA has higher upside potential than EssilorLuxottica SA, analysts believe Inventiva SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 IVAInventiva SA8 0 0 -
Is ESLOY or IVA More Risky?
EssilorLuxottica SA has a beta of 1.035, which suggesting that the stock is 3.545% more volatile than S&P 500. In comparison Inventiva SA has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.433%.
-
Which is a Better Dividend Stock ESLOY or IVA?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.25%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or IVA?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than Inventiva SA's net income of --. Notably, EssilorLuxottica SA's price-to-earnings ratio is 64.33x while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 5.63x versus 24.10x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA5.63x 64.33x -- -- IVAInventiva SA24.10x -- -- --
-
Which has Higher Returns ESLOY or NBTX?
Nanobiotix SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of 6.07% beat Nanobiotix SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B NBTXNanobiotix SA-- -- $24.3M -
What do Analysts Say About ESLOY or NBTX?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nanobiotix SA has an analysts' consensus of $14.74 which suggests that it could fall by -29.78%. Given that Nanobiotix SA has higher upside potential than EssilorLuxottica SA, analysts believe Nanobiotix SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 NBTXNanobiotix SA4 1 0 -
Is ESLOY or NBTX More Risky?
EssilorLuxottica SA has a beta of 1.035, which suggesting that the stock is 3.545% more volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ESLOY or NBTX?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.25%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or NBTX?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, EssilorLuxottica SA's price-to-earnings ratio is 64.33x while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 5.63x versus 29.34x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA5.63x 64.33x -- -- NBTXNanobiotix SA29.34x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
